Observational studyPharmacology research & perspectives2022

Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients.

Renate Kos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.